Solventum Corp

Listed Company

SOLVCIK 0001964738NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$8.32B

Net Income

$1.56B

Total Assets

$14.29B

Equity

$5.05B

Shares Out

173.49M

Op. Cash Flow

$369.00M

Business

Solventum Corp is a global healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, digital capabilities, and manufacturing expertise to address clinical and customer needs. It offers a broad portfolio of products and services across wound care, surgical supplies, dental and orthodontic products, health information software, and purification and filtration technologies. The company operates four business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Solventum distributes globally via direct sales, distributors, key account management, e-commerce, and local partners across over 90 countries.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Total net sales	8,325	8,254	8,197	8,130
Gross profit	4,451	4,593	4,693	4,695
Selling, general and administrative expenses	3,080	2,782	2,299	2,235
Research and development expenses	739	775	758	767
Gain on sale of business	−1,549	0	−56	—
Operating income	2,181	1,036	1,692	1,693
Interest expense, net	347	367	0	0
Loss on debt extinguishment, net	82	0	0	—
Other expense (income), net	39	64	25	1
Income before income taxes	1,713	605	1,667	1,692
Provision for income taxes	157	127	321	349
Net income	1,556	479	1,346	1,343
Basic earnings per share (in dollars per share)	8.94	2.77	7.79	7.78
Diluted earnings per share (in dollars per share)	8.88	2.76	7.79	7.78
Basic (in shares)	174	173	173	173
Diluted (in shares)	175	174	173	173

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	878	762	194	—	—
Accounts receivable net of allowances of $87 and $86	1,034	1,044	1,313	—	—
Due from related parties	150	185	0	—	—
Finished goods	636	539	453	—	—
Work in process	201	190	171	—	—
Raw materials and supplies	229	236	233	—	—
Total inventories	1,066	965	857	—	—
Other current assets	731	293	155	—	—
Total current assets	3,859	3,249	2,519	—	—
Property, plant and equipment net	1,326	1,622	1,457	—	—
Goodwill	5,704	6,377	6,535	6,434	—
Intangible assets net	2,592	2,544	2,902	—	—
Other assets	814	665	530	—	—
Total assets	14,294	14,457	13,943	—	—
Short-term borrowings and current portion of long-term debt	0	200	0	—	—
Accounts payable	687	618	477	—	—
Due to related parties	435	272	0	—	—
Unearned revenue	621	572	574	—	—
Other current liabilities	1,393	1,041	677	—	—
Total current liabilities	3,136	2,703	1,728	—	—
Long-term debt	5,035	7,810	0	—	—
Pension and postretirement benefits	363	350	166	—	—
Deferred income taxes	164	225	231	—	—
Other liabilities	547	410	152	—	—
Total liabilities	9,245	11,498	2,277	—	—
Commitments and contingencies (Note 12)	—	—	—	—	—
Common stock, par value $0.01 per share, 750,000,000 shares authorized	2	2	0	—	—
Additional paid-in-capital	3,876	3,771	0	—	—
Retained earnings	1,797	242	0	—	—
Accumulated other comprehensive income (loss)	−625	−1,056	−337	—	—
Total equity	5,049	2,959	11,666	11,742	12,059
Total liabilities and equity	14,294	14,457	13,943	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation and amortization	489	555	561	578
Pension and postretirement benefit expense	62	34	41	64
Stock-based compensation expense	161	112	39	37
Transaction costs	−111	0	0	—
Deferred income taxes	−120	−155	−142	−141
Accounts receivable	34	43	−129	−32
Due from related parties	44	233	0	0
Inventories	−139	−132	23	−82
Accounts payable	104	266	105	25
Due to related parties	−11	−395	0	0
Accrued compensation	43	78	142	—
All other operating activities - net	−194	67	−15	−113
Net cash provided by operating activities	369	1,185	1,915	1,679
Purchases of property, plant and equipment	−379	−380	−290	−251
Acquisitions, net of cash acquired	−696	0	0	—
Proceeds from sale of business	3,890	0	60	0
Other net	−18	0	0	−2
Net cash provided by (used in) investing activities	2,797	−380	−230	−253
Repayment of debt	−3,070	−300	0	0
Net transfers to 3M	−33	−8,251	−1,553	−1,456
Proceeds from long-term debt, net of issuance costs	0	8,303	0	0
Other net	46	8	1	−4
Net cash used in financing activities	−3,057	−240	−1,552	−1,460
Effect of exchange rate changes on cash and cash equivalents	7	3	0	4
Net increase (decrease) in cash and cash equivalents	116	568	133	−30
Income taxes	181	244	0	0
Interest	442	287	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro